1. Search Result
Search Result
Results for "

protein factor

" in MedChemExpress (MCE) Product Catalog:

241

Inhibitors & Agonists

17

Screening Libraries

1

Fluorescent Dye

6

Biochemical Assay Reagents

28

Peptides

1

MCE Kits

16

Inhibitory Antibodies

41

Natural
Products

1504

Recombinant Proteins

11

Isotope-Labeled Compounds

343

Antibodies

8

Click Chemistry

8

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P99571

    INH-H 2002

    Inhibitory Antibodies Infection
    Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
  • HY-P99769

    SCT-800

    Factor VIII Metabolic Disease
    Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
  • HY-P99830

    KH902

    VEGFR Cardiovascular Disease
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
  • HY-P99720
    Luspatercept
    2 Publications Verification

    ACE-536; luspatercept–aamt

    TGF-beta/Smad Metabolic Disease Cancer
    Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
  • HY-P99879

    Benegrastim; Bineuta; F 627

    STAT Inflammation/Immunology
    Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
  • HY-P991178

    TNF Receptor Cancer
    BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
  • HY-112998

    Factor VIII Others
    Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
  • HY-P99782

    TNF Receptor Inflammation/Immunology
    Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .
  • HY-P991067

    KP-104

    Complement System Inflammation/Immunology
    Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
  • HY-P3385

    SCB-313

    Drug Derivative Apoptosis Cancer
    Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .
  • HY-P99913

    c-Fms Inflammation/Immunology Cancer
    Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
  • HY-P99590

    ACE-011

    TGF-β Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
  • HY-P9958
    Denosumab
    1 Publications Verification

    AMG-162

    NF-κB Caspase Apoptosis RANKL/RANK Endocrinology Cancer
    Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
  • HY-P9958A
    Denosumab (anti-TNFSF11)
    1 Publications Verification

    RANKL/RANK Apoptosis NF-κB Neurological Disease Endocrinology Cancer
    Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
  • HY-P99666

    IFNAR Infection Cancer
    Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
  • HY-P99941

    PD-1/PD-L1 Cancer
    Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: